Literature DB >> 28668829

Effect of Lonidamine on Systemic Therapy of DB-1 Human Melanoma Xenografts with Temozolomide.

Kavindra Nath1, David S Nelson2, Jeffrey Roman2, Mary E Putt3, Seung-Cheol Lee2, Dennis B Leeper4, Jerry D Glickson2.   

Abstract

BACKGROUND/AIM: Since temozolomide (TMZ) is activated under alkaline conditions, we expected lonidamine (LND) to have no effect or perhaps diminish its activity, but initial results suggest it may actually enhance either or both short- and long-term activity of TMZ in melanoma xenografts.
MATERIALS AND METHODS: Cohorts of 5 mice with subcutaneous xenografts ~5 mm in diameter were treated with saline (control (CTRL)), LND only, TMZ only or LND followed by TMZ at t=40 min (time required for maximal tumor acidification).
RESULTS: Mean tumor volume for LND+TMZ for the period between 6 and 26 days was reduced compared to TMZ alone (repeated measures ANOVA F (1, 8), p=0.006), suggesting a pronounced impact of LND on this phenomenon. TMZ and LND+TMZ produced median growth delays of 82 and 106 days, respectively.
CONCLUSION: The use of TMZ alone and in combination with LND deserves further investigation in treatment of melanoma and other malignancies. Copyright
© 2017, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.

Entities:  

Keywords:  Melanoma; lonidamine; temozolomide; tumor acidification; tumor deenergization

Mesh:

Substances:

Year:  2017        PMID: 28668829      PMCID: PMC8757536          DOI: 10.21873/anticanres.11708

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  54 in total

Review 1.  The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.

Authors:  Kathleen M Mahoney; Gordon J Freeman; David F McDermott
Journal:  Clin Ther       Date:  2015-03-29       Impact factor: 3.393

2.  Mechanisms of DNA sequence selective alkylation of guanine-N7 positions by nitrogen mustards.

Authors:  K W Kohn; J A Hartley; W B Mattes
Journal:  Biochem Pharmacol       Date:  1988-05-01       Impact factor: 5.858

3.  Lonidamine: a hyperthermic sensitizer of HeLa cells in culture and of the Meth-A tumor in vivo.

Authors:  J H Kim; S H Kim; A Alfieri; C W Young; B Silvestrini
Journal:  Oncology       Date:  1984       Impact factor: 2.935

4.  Noninvasive real-time monitoring of intracellular cancer cell metabolism and response to lonidamine treatment using diffusion weighted proton magnetic resonance spectroscopy.

Authors:  Y Mardor; O Kaplan; M Sterin; J Ruiz-Cabello; E Ash; Y Roth; I Ringel; J S Cohen
Journal:  Cancer Res       Date:  2000-09-15       Impact factor: 12.701

5.  Lonidamine induces intracellular tumor acidification and ATP depletion in breast, prostate and ovarian cancer xenografts and potentiates response to doxorubicin.

Authors:  Kavindra Nath; David S Nelson; Daniel F Heitjan; Dennis B Leeper; Rong Zhou; Jerry D Glickson
Journal:  NMR Biomed       Date:  2014-12-12       Impact factor: 4.044

Review 6.  Immune Checkpoint Blockade in Cancer Therapy.

Authors:  Michael A Postow; Margaret K Callahan; Jedd D Wolchok
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

7.  A phase I study of TPI 287 in combination with temozolomide for patients with metastatic melanoma.

Authors:  Jennifer L McQuade; Liberty P Posada; Srisuda Lecagoonporn; Suzanne Cain; Roland L Bassett; Sapna P Patel; Wen-Jen Hwu; Patrick Hwu; Michael A Davies; Agop Y Bedikian; Rodabe N Amaria
Journal:  Melanoma Res       Date:  2016-12       Impact factor: 3.599

Review 8.  Treatment of malignant pheochromocytoma.

Authors:  R Adjallé; P F Plouin; K Pacak; H Lehnert
Journal:  Horm Metab Res       Date:  2009-08-11       Impact factor: 2.936

9.  Increasing incidence of cutaneous melanoma in Queensland, Australia.

Authors:  R MacLennan; A C Green; G R McLeod; N G Martin
Journal:  J Natl Cancer Inst       Date:  1992-09-16       Impact factor: 13.506

Review 10.  Chemotherapy and role of the proliferation marker Ki-67 in digestive neuroendocrine tumors.

Authors:  Eduardo Vilar; Ramón Salazar; Jose Pérez-García; Javier Cortes; Kjell Oberg; Josep Tabernero
Journal:  Endocr Relat Cancer       Date:  2007-06       Impact factor: 5.678

View more
  2 in total

Review 1.  The Potential of Lonidamine in Combination with Chemotherapy and Physical Therapy in Cancer Treatment.

Authors:  Yaxin Huang; Guohui Sun; Xiaodong Sun; Feifan Li; Lijiao Zhao; Rugang Zhong; Yongzhen Peng
Journal:  Cancers (Basel)       Date:  2020-11-11       Impact factor: 6.639

2.  Effect of Differences in Metabolic Activity of Melanoma Models on Response to Lonidamine plus Doxorubicin.

Authors:  Kavindra Nath; Jeffrey Roman; David S Nelson; Lili Guo; Seung-Cheol Lee; Stepan Orlovskiy; Kevin Muriuki; Daniel F Heitjan; Stephen Pickup; Dennis B Leeper; Ian A Blair; Mary E Putt; Jerry D Glickson
Journal:  Sci Rep       Date:  2018-10-02       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.